New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out
Loading...
Shape
ACADIA Pharmaceuticals Inc.
ACAD
Shape
US Flag

NASDAQ

2B

Biotechnology

Next Earning date - 06 Nov 2024

2B

Biotechnology

Next Earning date - 06 Nov 2024

14.54USD
Shape0.06 ( 0.42%)
Market Open
favorite-chart

Relative Strenght

11
favorite-chart

Volume Buzz

-93%
favorite-chart

Earning Acce

No
favorite-chart

Dist 52w H.

55%

Quote Panel

Shape
Updated October 25, 2024
1W -1.69 % 1M -6.27 % 3M -24.19 % 1Y -35.51 %

Key Metrics

Shape
  • Market Cap

    2.41B


  • Shares Outstanding

    165.88M


  • Share in Float

    164.61M


  • Dividende

    0


  • Earning Date

    06 Nov 2024


  • Price Target

    14.54


  • Average Volume

    1.55M


  • Beta

    0.383


  • Range

    14.15-32.59


  • Industry

    Biotechnology


  • Website

    https://www.acadia-pharm.com


  • Sector

    Healthcare


Fundamentals

Shape

80.61x

P/E Ratio

2.69x

P/S Ratio

4.63x

P/B Ratio

0.1

Debt/Equity

3.4%

Net Margin

$0.2

EPS

How ACAD compares to sector?

P/E Ratio

Relative Strength

Shape

ACAD

Sector

loading...

Top 5 RS in Group

Symbol

Company

RS

5-Day Perf.

Forecast

Shape

$1B

Shape335%

2025-Revenue

$0.82

Shape310%

2025-EPS

$475M

Shape-1538%

2025-EBITDA

Analyst rating

No Data Available

Last analyst upgrade/downgrade

Morgan Stanley

downgrade

Previous: Overweight

2024-08-07

Now: Equal-Weight

BMO Capital

initialise

Previous: Buy

2024-06-26

Now: Outperform

Needham

upgrade

Previous: Hold

2024-01-24

Now: Buy

Morgan Stanley

upgrade

Previous: Equal-Weight

2023-12-19

Now: Overweight

Earnings GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

N/A

-0.17
vs -0.09

Q4.22

arrow
arrow

N/A

-0.26
vs -0.27

Q1.23

arrow
arrow

N/A

-0.27
vs -0.70

Q2.23

arrow
arrow

+105%

0.01
vs -0.21

Q3.23

arrow
arrow

N/A

-0.40
vs -0.17

Q4.23

arrow
arrow

+208%

0.28
vs -0.26

Q1.24

arrow
arrow

+137%

0.1
vs -0.27

Q2.24

arrow
arrow

+1900%

0.2
vs 0.01

Q3.24

arrow
arrow

+131%

0.13
vs -0.40

Q4.24

arrow
arrow

-59%

0.11
vs 0.28

Sales GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

-1%

130.7M  vs 131.6M

Q4.22

arrow
arrow

+4%

136.5M  vs 130.8M

Q1.23

arrow
arrow

+3%

118.5M  vs 115.5M

Q2.23

arrow
arrow

+23%

165.2M  vs 134.6M

Q3.23

arrow
arrow

+62%

211.7M  vs 130.7M

Q4.23

arrow
arrow

+69%

231M  vs 136.5M

Q1.24

arrow
arrow

+74%

205.8M  vs 118.5M

Q2.24

arrow
arrow

+46%

242M  vs 165.2M

Q3.24

arrow
arrow

+17%

248.7M  vs 211.7M

Q4.24

arrow
arrow

+11%

255.6M  vs 231M

Return on EquityShape

status-upQoQ

Q3.22

arrow
arrow

-6%

-0.06
vs -0.08

Q4.22

arrow
arrow

-10%

-0.10
vs -0.06

Q1.23

arrow
arrow

-11%

-0.11
vs -0.10

Q2.23

arrow
arrow

+0%

0
vs -0.11

Q3.23

arrow
arrow

-18%

-0.18
vs 0

Q4.23

arrow
arrow

+11%

0.11
vs -0.18

Q1.24

arrow
arrow

+4%

0.04
vs 0.11

Q2.24

arrow
arrow

+6%

0.06
vs 0.04

Institutionnal OwnershipShape

status-upQoQ

Q3.22

arrow
arrow

231

231
vs 259

-11%

Q4.22

arrow
arrow

237

237
vs 231

3%

Q1.23

arrow
arrow

245

245
vs 237

3%

Q2.23

arrow
arrow

244

244
vs 245

0%

Q3.23

arrow
arrow

264

264
vs 244

8%

Q4.23

arrow
arrow

294

294
vs 264

11%

Q1.24

arrow
arrow

288

288
vs 294

-2%

Q2.24

arrow
arrow

275

275
vs 288

-5%

Earnings Growth

Latest News